Stock Financial Ratios

AVIR / Aviragen Therapeutics, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)21.64
Enterprise Value ($M)8.77
Book Value ($M)18.70
Book Value / Share0.48
Price / Book1.56
NCAV ($M)30.10
NCAV / Share0.78
Price / NCAV0.74
Income Statement (mra) ($M)
Net Income-29.40
Balance Sheet (mrq) ($M)
Cash & Equivalents19.60
Cash / Share0.51
Quick Ratio3.99
Current Ratio3.99
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-1.57
Return on Assets (ROA)-0.73
Return on Equity (ROE)-1.57
Identifiers and Descriptors
Central Index Key (CIK)72444
Industry Groups
SIC 2836 - Biological Products, Except Diagnostic Substances (Biotech)
Other Related CUSIPS
Share Statistics
Common Shares Outstanding (M)38.65
Scoring Models
Piotroski F Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Inventory Work In Progress Per Share0.00
Liabilities Current Per Share0.13
Long Term Debt Per Share0.00
Treasury Stock Per Share0.00
Accounts Payable Per Share0.00
Property Plant And Equipment Net Per Share0.01
Debt Per Share0.00
Assets Per Share0.90
Inventory Per Share0.00
Liabilities Per Share0.13
Assets Current Per Share0.89
Assets Other Non Current Per Share0.00
Intangibles Per Share0.00
Retained Earnings Per Share-4.38
Goodwill Per Share0.00
Cash And Equivalents Per Share0.51
Deferred Income Tax Liabilities Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Accounts Receivable Per Share0.00
Inventory Raw Materials Per Share0.00
Equity Per Share0.36
Assets Other Current Per Share0.00
Property Plant And Equipment Per Share0.01
Inventory Finished Goods Per Share0.00
Liabilities Other Non Current Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Accumulated Depreciation And Depletion Per Share0.00
Additional Paid In Capital Per Share4.14
Cash Per Share0.51
Minority Interest Per Share0.00
Liabilities And Stock Equity Per Share0.90

Stock Research Report

Aviragen Therapeutics is focused on the discovery and development of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has three Phase 2 clinical stage compounds: BTA074, an antiviral treatment for condyloma caused by human papillomavirus types 6 & 11; vapendavir, a capsid inhibitor for the prevention or treatment of rhinovirus (RV) upper respiratory infections; and BTA585 (enzaplatovir), a fusion protein inhibitor in development for the treatment of respiratory syncytial virus infections. The company also have a preclinical RSV non-fusion inhibitor program.

In April 2017, the company engaged Stifel, Nicolaus and Company, Incorporated (“Stifel”) as its advisor to assist with the exploration of strategic alternatives (the “Strategic Review”). Stifel is providing a range of advisory services aimed to enhance stockholder value. The alternatives to be considered may include, but are not l...

Click for full article

Related News Stories

Corporate News Blog - Aviragen Enters Into Merger Agreement with Vaxart

2017-11-01 accesswire
LONDON, UK / ACCESSWIRE / November 1, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Aviragen Therapeutics, Inc, (NASDAQ: AVIR) (""Aviragen), following which we have published a free report that can be viewed by signing up at The Company announced on October 30, 2017, that it has entered into a definitive merger agreement with Vaxart Inc. (74-2)

BRIEF-SC Fundamental Value Fund LP reports 5.01 pct stake in Aviragen Therapeutics Inc as of June 21

2017-06-30 reuters
* SC Fundamental Value Fund Lp reports 5.01 percent stake in Aviragen Therapeutics Inc as of June 21 - SEC filing Source text - ( Further company coverage:

BRIEF-East Hill Management says Aviragen Therapeutics "should wind up its business and liquidate"

2017-06-19 reuters
* East Hill Management says Aviragen Therapeutics "should abandon all of its plans to explore strategic alternatives and instead should wind up its business and liquidate"

CUSIP: 053761102